Business
SciSparc Signs Agreement for the Supply of CBD-rich Cannabis Oil for its Clinical Trial on Children with Autism Spectrum Disorder
The cannabis oil will be used as a part of the Company's proprietary SCI-210 treatment combination of CBD and CannAmide™ TEL AVIV, Israel, Feb. 27, 2023
About this update from Scisparc Ltd.
[{"type":"text","content":"The cannabis oil will be used as a part of the Company's proprietary SCI-210 treatment combination of CBD and CannAmide™ TEL AVIV, Israel, Feb. 27, 2023 (GLOBE NEWSWIRE) -- SciSparc Ltd. (Nasdaq: SPRC) (\"Company\" or \"SciSparc\"), a specialty clinical-stage pharmaceutical company focusing on the development of therapies to treat disorders of the central nervous system, today announced it has signed an agreement with Israel's leading and pioneer manufacturer and distributer of cannabis-based products, Tikun Olam Cannbit Pharmaceuticals Ltd., Israel (TASE: TKUN), to supply CBD-rich oil from Cannbit strains by, to be used as part of its proprietary SCI-210 treatment, which is a combination of CBD and CannAmide™. SCI-210 treatment will be used in the Company's clinical trial (\"Trial\") on children with autism spectrum disorder (“ASD”). The Trial will be conducted at the Soroka University Medical Center, led by Prof. Gal Meiri, head of the Soroka Preschool Psychiatry Unit. The Company has already secured approvals from the Israeli Ministry of Health as well as the Ethics Committee of the Soroka University Medical Center to conduct the Company’s clinical trial. The Trial will evaluate the safety, tolerability and efficacy of SciSparc’s drug candidate SCI-210, a proprietary combination of cannabidiol (“CBD”) and CannAmide™, in comparison to CBD monotherapy in children with ASD. The study design is a 20-week, randomized double-blind placebo-controlled with cross-over clinical trial on 60 children. The trial has three primary efficacy end points: the Aberrant Behavior Checklist-Community parent questionnaire; the Clinical Global Impressions-Improvement performed by a clinician; and the effective therapeutic dose. \"We are nearing the end of our preparations to begin our clinical trial on children with autism spectrum disorder. Our partners are chosen for their experience, quality, and deep knowledge in the relevant fields,\" said Oz Adler, Chief Executive Officer of SciSparc. \"Since clinical trials on children are extremely strict, and it is one of the populations most in need of these treatments, we are proud of the approvals we have received so far.\" ASD is a condition related to brain development that impacts how a person perceives and socializes with others, causing problems in social interaction and communication. The term \"sp...